Information
-
Trademark
-
88891086
-
International Classifications
-
Filing Date
April 28, 2020
4 years ago
-
Transaction Date
September 09, 2024
4 months ago
-
Status Date
September 09, 2024
4 months ago
-
Published for Opposition Date
July 19, 2022
2 years ago
-
Location Date
September 13, 2022
2 years ago
-
Status Code
733
-
Current Location
INTENT TO USE SECTION
Employee Name
DETMER, CAROLYN
-
Attorney Docket Number
16305005UST1
Attorney Name
Peter Kunin
Law Office Assigned Location Code
N90
-
Owners
Mark Drawing Code
4
Mark Identification
PINPOINT
Case File Statements
- GS0421: Services in the field of computer assisted research in the nature of pharmaceutical research in the field of research and development of therapeutic biomolecules, namely, bioinformatics services directed to immune-engaging therapeutic biomolecule research and development; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely services to analyze immunotherapy treatments, including treatment of cancer, autoimmune disease, infectious disease, fibrotic disease, or cellular senescence; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely, services using comparative analysis across diseased and healthy tissue, between patients, between cells, comparing protein expression and surface localization information, and analysis of preclinical and clinical data from therapeutic biomolecules, to identify targets for immunotherapy development; all of the foregoing excluding providing temporary use of non-downloadable computer software for data mining, data query, and data analysis excluding providing temporary use of non-downloadable computer software for applying statistical, econometric, and machine learning methods to data sets to generate data transformations and analyses and for displaying, visualizing, and interpreting the results of these data transformations and analyses; excluding providing temporary use of non-downloadable computer software, namely, educational software featuring instruction, testing, and assessment in the fields of statistics, econometrics, and machine learning for secondary, postsecondary and skills education; excluding biological preparations biological preparations in the nature of eukaryotic cells, isogenic cell lines and bio-production cell lines generated using base editing engineering for scientific, laboratory or medical research; excluding reagents, plasmids and assays for scientific, genetic and medical research; excluding genomic reference control samples for medical laboratory use; excluding molecular biology research tools, in the nature of chemical, biological and biochemical reagents; excluding biological preparations in the nature of separate base editing components including mRNA, rRNA, gRNA, deaminase, nickase, ribonucleotide protein (RNP) for use in scientific, laboratory or medical research; excluding biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; excluding biological and chemical reagents including complexes of these molecules for research and for clinical and industrial use; excluding diagnostic preparations and materials generated by the use of base editing components for medical purposes; excluding chemical preparation for use in DNA analysis for medical purposes; excluding biological preparations in the nature of DNA, RNA and parts thereof for medical purposes; excluding biological preparations in the nature of DNA extracts for medical purposes; excluding biological preparations in the nature of gene editing enzymes for medical purposes; excluding biological preparations in the nature of protein cell lysates, genomic DNA preparations and Formalin Fixed, Paraffin Embedded (FFPE) engineered tumour tissue mimics for medical diagnostic use; excluding biological preparations in the nature of biological, biochemical and chemical reagents, including living cells, genetically modified cells and vectors, genomic DNA, cell cultures and mutant and normal isogenic cell line pairs, peptides, proteins and nucleic acids or complexes of these molecules for medical use; excluding collections of DNA and gene sequences for research and reference purposes provided as DNA microarrays and DNA chips; excluding treatment of biopharmaceutical materials; excluding custom manufacture of cells and vectors for diagnostic, medical and commercial applications in relation to cell and gene therapies; excluding custom cell-line engineering services; excluding gene base-editing services for research purposes; excluding gene engineering services; excluding research and development services in the creation of databases or collections of information on biologicals including cells and cell lines for research purposes; excluding creating and providing databases or collections of information on normal and mutated genes for research purposes; excluding providing DNA reference standards for research purposes; excluding providing DNA reference databases being collections of DNA and gene sequences for research purposes; excluding research on cell line models; excluding contract research on cell line models; excluding research and development services relating to targeting therapies to individuals; excluding establishing patient genotypes for research or analysis purposes; excluding research and development services relating to combining therapies for individuals; excluding research and development relating to reagents; excluding disease modelling for research purposes; excluding design of clinical trials for research purposes; excluding research and development in re-positioning existing drugs from other therapeutic indications; excluding services relating to biological and medical research and research and development in the field of cells and cell therapies, genome editing, genetic engineering and gene therapies
Case File Event Statements
-
8/7/2020 - 4 years ago
4 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
5/1/2020 - 4 years ago
1 - NEW APPLICATION ENTERED
Type: NWAP
-
5/8/2020 - 4 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
7/22/2020 - 4 years ago
3 - ASSIGNED TO EXAMINER
Type: DOCK
-
2/8/2021 - 3 years ago
8 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
8/7/2020 - 4 years ago
5 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
8/7/2020 - 4 years ago
6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
2/8/2021 - 3 years ago
7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
2/9/2021 - 3 years ago
9 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
4/19/2021 - 3 years ago
10 - SUSPENSION LETTER WRITTEN
Type: CNSL
-
4/19/2021 - 3 years ago
11 - LETTER OF SUSPENSION E-MAILED
Type: GNSL
-
4/19/2021 - 3 years ago
12 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Type: GNS3
-
8/23/2021 - 3 years ago
13 - ASSIGNED TO EXAMINER
Type: DOCK
-
10/27/2021 - 3 years ago
14 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Type: RCCK
-
5/23/2022 - 2 years ago
18 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
11/23/2021 - 3 years ago
15 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
11/23/2021 - 3 years ago
16 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
11/23/2021 - 3 years ago
17 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
5/23/2022 - 2 years ago
19 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
5/27/2022 - 2 years ago
20 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
6/16/2022 - 2 years ago
21 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
7/19/2022 - 2 years ago
24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
6/29/2022 - 2 years ago
22 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
7/19/2022 - 2 years ago
23 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
9/13/2022 - 2 years ago
25 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Type: NOAM
-
2/20/2023 - a year ago
28 - SOU EXTENSION 1 GRANTED
Type: EX1G
-
2/20/2023 - a year ago
26 - SOU TEAS EXTENSION RECEIVED
Type: EEXT
-
2/20/2023 - a year ago
27 - SOU EXTENSION 1 FILED
Type: EXT1
-
3/6/2024 - 10 months ago
35 - SOU EXTENSION 3 FILED
Type: EXT3
-
2/22/2023 - a year ago
29 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
9/11/2023 - a year ago
30 - SOU TEAS EXTENSION RECEIVED
Type: EEXT
-
9/11/2023 - a year ago
31 - SOU EXTENSION 2 FILED
Type: EXT2
-
9/11/2023 - a year ago
32 - SOU EXTENSION 2 GRANTED
Type: EX2G
-
9/13/2023 - a year ago
33 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
3/6/2024 - 10 months ago
34 - SOU TEAS EXTENSION RECEIVED
Type: EEXT
-
3/6/2024 - 10 months ago
36 - SOU EXTENSION 3 GRANTED
Type: EX3G
-
3/7/2024 - 10 months ago
37 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
9/9/2024 - 4 months ago
38 - SOU TEAS EXTENSION RECEIVED
Type: EEXT
-
9/9/2024 - 4 months ago
41 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
9/9/2024 - 4 months ago
39 - SOU EXTENSION 4 FILED
Type: EXT4
-
9/9/2024 - 4 months ago
40 - SOU EXTENSION 4 GRANTED
Type: EX4G